BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16645618)

  • 41. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
    Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
    Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.
    Lombardi V; Van Overtvelt L; Horiot S; Moingeon P
    J Immunol; 2009 Mar; 182(6):3372-9. PubMed ID: 19265114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells.
    Li B; He X; Pang X; Zhang H; Chen J; Chen W
    Scand J Immunol; 2004 Nov; 60(5):506-13. PubMed ID: 15541044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
    Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Melanoma skews dendritic cells to facilitate a T helper 2 profile.
    McCarter M; Clarke J; Richter D; Wilson C
    Surgery; 2005 Aug; 138(2):321-8. PubMed ID: 16153443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma.
    Tanaka A; Minoguchi K; Samson KT; Oda N; Yokoe T; Tazaki T; Yamamoto Y; Yamamoto M; Ohta S; Adachi M
    Clin Exp Allergy; 2007 Jul; 37(7):1083-9. PubMed ID: 17581203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
    Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
    Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SLC gene-modified dendritic cells mediate T cell-dependent anti-gastric cancer immune responses in vitro.
    Xue G; Cheng Y; Ran F; Li X; Huang T; Yang Y; Zhang Y
    Oncol Rep; 2013 Feb; 29(2):595-604. PubMed ID: 23229068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethanol consumption modifies dendritic cell antigen presentation in mice.
    Heinz R; Waltenbaugh C
    Alcohol Clin Exp Res; 2007 Oct; 31(10):1759-71. PubMed ID: 17850646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of dendritic cell interleukin-12 secretion by tumour cell necrosis.
    Kandil H; Bachy V; Williams DJ; Helmi R; Gotch FM; Ibrahim MA
    Clin Exp Immunol; 2005 Apr; 140(1):54-64. PubMed ID: 15762875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
    J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
    Liu Y; Bi X; Xu S; Xiang J
    Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells.
    Haenssle HA; Riedl P; Buhl T; Schardt A; Rosenberger A; Schön MP; Schirmbeck R
    Exp Dermatol; 2010 Jan; 19(1):19-28. PubMed ID: 19758325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.